{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-047073","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.320261+00:00","generated_at":"2026-06-05T11:34:19.174383+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apellis FY2023 revenue $396.6M, SYFOVRE drives 160k+ doses; net loss $528.6M","bullets":["Full year 2023 total revenue $396.6M (vs $75.4M in 2022); SYFOVRE $275.2M, EMPAVELI $91.0M.","SYFOVRE: over 160,000 commercial and sample doses distributed in 2023; Q4 net revenue $114.3M.","Net loss $528.6M for 2023 (vs $652.2M in 2022); cash $351.2M as of Dec 31, 2023.","Entered agreements to unwind ~80% of capped calls on convertible notes due 2026; expects ~$100M proceeds.","G&A expenses rose to $500.8M in 2023 (vs $277.2M in 2022) on SYFOVRE commercial launch costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-047073","json":"https://secwatch.observer/filing/0001193125-24-047073.json","markdown":"https://secwatch.observer/filing/0001193125-24-047073.md","text":"https://secwatch.observer/filing/0001193125-24-047073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/0001193125-24-047073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/d796432d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:34:19.174383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf8fac7843b9124e8485b773d05bc564a398f2a0","claim":"Apellis Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $396.6 million.","evidence_excerpt":"For the full year 2023, total revenue was $396.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/0001193125-24-047073-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$396.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c6d7a464932e79ec924f754416f0300e6dcb5633","claim":"Apellis Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $146.4 million.","evidence_excerpt":"Total revenue was $146.4 million for the fourth quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/0001193125-24-047073-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$146.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}